ASCO 2015 Highlights

Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis.
Read Article

The AVBCC Summit Is for Everyone
Elizabeth Beisel, Swim Across America Representative, attended the AVBCC Summit to learn from some of the "most brilliant minds" in cancer care today after having lost her father to pancreatic cancer earlier in the year.
Read Article

Insights into Research Funding at AVBCC Summit
Learning about the next steps in cancer research funding was an eye-opening discussion topic for Elizabeth Beisel, Swim Across America Representative.
Read Article

Hope for the Future
Swim Across America raises about $10 million per year and the AVBCC Summit helps clarify how the money should be allocated and instils hope for the future.
Read Article

Patient-Centered Cancer Care Is the Main Goal
Creating truly patient-centered cancer care would be the main goal of Elizabeth Beisel, Swim Across America Representative.
Read Article

Continuing the Learning Process
As a newcomer to the oncology world, Elizabeth Beisel, Swim Across America Representative, looks forward to attending the next AVBCC Summit to build on all she has learned from her first meeting.
Read Article

Amazing Array of Experts at AVBCC Summit
Jack Salerno, Managing Partner, SBD Partners, says he has attended the AVBCC Summit for the past 4 years because "it is a really great event with an amazing array of experts in oncology healthcare."
Read Article

It's Personal and Professional for This Attendee
Key takeaways for Jack Salerno, Managing Partner, SBD Partners, are personal and professional. He mentions the energy, passion, and commitment on display at each summit.
Read Article

Listening to Learn at AVBCC Summit
"You don't learn anything when you're talking; you learn when you listen," and Jack Salerno, Managing Partner, SBD Partners, comes to learn and share information for better patient outcomes.
Read Article

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib.
Read Article

Page 34 of 330